These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18430791)

  • 1. Confirmed beta16 Arg/Arg polymorphism in a patient with uncontrolled asthma.
    Metzger NL; Kockler DR; Gravatt LA
    Ann Pharmacother; 2008 Jun; 42(6):874-81. PubMed ID: 18430791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response.
    Peters S
    Curr Med Res Opin; 2007 Sep; 23 Suppl 3():S29-36. PubMed ID: 17925066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of tiotropium for patients with asthma.
    Bollmeier SG; Lee SY
    Ann Pharmacother; 2013 May; 47(5):704-13. PubMed ID: 23613100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD.
    Umeda N; Yoshikawa T; Kanazawa H; Hirata K; Fujimoto S
    Respirology; 2008 May; 13(3):346-52. PubMed ID: 18399855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tachyphylaxis to beta2-agonists in Spanish asthmatic patients could be modulated by beta2-adrenoceptor gene polymorphisms.
    Tellería JJ; Blanco-Quirós A; Muntión S; Antonio Garrote J; Arranz E; Armentia A; Díez I; Castro J
    Respir Med; 2006 Jun; 100(6):1072-8. PubMed ID: 16263254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    Israel E; Drazen JM; Liggett SB; Boushey HA; Cherniack RM; Chinchilli VM; Cooper DM; Fahy JV; Fish JE; Ford JG; Kraft M; Kunselman S; Lazarus SC; Lemanske RF; Martin RJ; McLean DE; Peters SP; Silverman EK; Sorkness CA; Szefler SJ; Weiss ST; Yandava CN
    Am J Respir Crit Care Med; 2000 Jul; 162(1):75-80. PubMed ID: 10903223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is new with the beta2-agonists: issues in the management of asthma.
    Kelly HW
    Ann Pharmacother; 2005 May; 39(5):931-8. PubMed ID: 15811904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a problem with inhaled long-acting beta-adrenergic agonists?
    Nelson HS
    J Allergy Clin Immunol; 2006 Jan; 117(1):3-16; quiz 17. PubMed ID: 16387577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL; Baker EL; Coleman CI
    Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of β(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.
    Giubergia V; Gravina L; Castaños C; Chertkoff L
    Ann Allergy Asthma Immunol; 2013 Mar; 110(3):156-60. PubMed ID: 23548523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM; Bollmeier SG; Finnegan PM
    Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
    Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
    Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response.
    Park HW; Yang MS; Park CS; Kim TB; Moon HB; Min KU; Kim YY; Cho SH
    Allergy; 2009 May; 64(5):778-83. PubMed ID: 19183167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.
    Drescher GS; Carnathan BJ; Imus S; Colice GL
    Respir Care; 2008 Dec; 53(12):1678-84. PubMed ID: 19025702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A safety review of long-acting beta2-agonists in patients with asthma.
    Rider NL; Craig TJ
    J Am Osteopath Assoc; 2006 Sep; 106(9):562-7. PubMed ID: 17079526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical consequences of ADRbeta2 polymorphisms.
    Hawkins GA; Weiss ST; Bleecker ER
    Pharmacogenomics; 2008 Mar; 9(3):349-58. PubMed ID: 18303970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
    Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
    Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of risk factors and health outcomes among persons with asthma.
    Smith K; Warholak T; Armstrong E; Leib M; Rehfeld R; Malone D
    J Asthma; 2009 Apr; 46(3):234-7. PubMed ID: 19373629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADRB2 Gly16Arg polymorphism, asthma control and lung function decline.
    Rebordosa C; Kogevinas M; Guerra S; Castro-Giner F; Jarvis D; Cazzoletti L; Pin I; Siroux V; Wjst M; Antò JM; de Marco R; Estivill X; Corsico AG; Nielsen R; Janson C
    Eur Respir J; 2011 Nov; 38(5):1029-35. PubMed ID: 21436355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children.
    Giubergia V; Gravina LP; Castaños C; Chertkoff L; Grenoville M
    Pediatr Pulmonol; 2008 May; 43(5):421-5. PubMed ID: 18383333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.